All In Biotech

Drug Trial Radar · NCT02477800

221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease

A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease

Last checked: Nov 20, 2026Latest source record: Sep 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,653 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

1,653

Actual

Start

Aug 13, 2015

Primary completion

Aug 8, 2019

Study completion Aug 8, 2019

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Jun 23, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 85 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to evaluate the efficacy of monthly doses of aducanumab in slowing cognitive and functional impairment as measured by changes in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score as compared with placebo in participants with early AD. Secondary objectives are to assess the effect of monthly doses of aducanumab as compared with placebo on clinical progression as measured by Mini-Mental State Examination (MMSE), AD Assessment Scale-Cognitive Subscale (13 items) \[ADAS-Cog 13\], and AD Cooperative Study-Activities of Daily Living Inventory (Mild Cognitive Impairment version) \[ADCS-ADL-MCI\].

Conditions

  • Alzheimer's Disease

Interventions

  • Aducanumab (BIIB037)Drug

    Low dose

  • Aducanumab (BIIB037)Drug

    High dose

  • PlaceboDrug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB) Score at Week 78Time frame: Baseline, Week 78

Locations

181 sites in 14 countries. Site status is shown where the registry gives one.

  • St. Joseph's Hospital and Medical Center

    Phoenix, Arizona

  • Center for Neurosciences

    Tucson, Arizona

  • Neurology Center of North Orange County

    Fullerton, California

  • Senior Clinical Trials, Inc.

    Laguna Hills, California

  • Torrance Clinical Research Institute, Inc.

    Lomita, California

  • University of California - Los Angeles

    Los Angeles, California

  • UCSF - Memory and Aging Center

    San Francisco, California

  • California Neuroscience Research Medical Group Inc.

    Sherman Oaks, California

  • Southern California Research LLC

    Simi Valley, California

  • Institute for Neurodegenerative Disorders

    New Haven, Connecticut

  • Georgetown University Hospital

    Washington D.C., District of Columbia

  • Brain Matters Research, Inc.

    Delray Beach, Florida

  • Neuropsychiatric Research Center of Southwest Florida

    Fort Myers, Florida

  • Jacksonville Center for Clinical Research

    Jacksonville, Florida

  • University of Miami

    Miami, Florida

  • Miami Jewish Health Systems

    Miami, Florida

  • Compass Research Main

    Orlando, Florida

  • Palm Beach Neurological Center

    Palm Beach Gardens, Florida

  • Stedman Clinical Trials, LLC

    Tampa, Florida

  • USF Health Byrd Institute

    Tampa, Florida

  • Meridien Research

    Tampa, Florida

  • Compass Research Main

    The Villages, Florida

  • Premiere Research Institute

    West Palm Beach, Florida

  • Cleveland Clinic Florida - Weston

    Weston, Florida

  • Alexian Brothers Neurosciences Institute

    Elk Grove Village, Illinois

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois

  • Fort Wayne Neurological Center

    Fort Wayne, Indiana

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • University of Kansas Medical Center Research Institute, Inc.

    Kansas City, Kansas

  • Via Christi Research, a division of Via Christi Hospitals Wichita, Inc.

    Wichita, Kansas

  • Baptist Health Lexington

    Lexington, Kentucky

  • Brigham & Women's Hosp End/Dbt

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • ActivMed Practices & Research

    Methuen, Massachusetts

  • Donald S. Marks, M.D., P.C.

    Plymouth, Massachusetts

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University

    St Louis, Missouri

  • Las Vegas Medical research

    Las Vegas, Nevada

  • Advanced Memory Research Institute of NJ, PC

    Toms River, New Jersey

  • Albany Medical College

    Albany, New York

Showing 40 of 181 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.